Ionis Pharmaceuticals stock kpis
Want to see IONS full AI Analyst Report?
Revenue by Segment
Ionis Pharmaceuticals reported revenue by segment of $267.90M in Q2 2026, up 8.9% from Q1 2026 and down 40.7% year over year. The highest value was $452.05M in Q2 2025.
Breaks down revenue by business segments, revealing the company's strategic focus areas and how each segment contributes to overall financial performance.
Ionis’ top line is transitioning from lumpy, milestone-driven R&D/collaboration receipts to meaningful, scaling product sales: 2025 shows a clear commercial ramp as launches and growing royalties supplement still‑large but episodic R&D income. That mix creates pronounced quarter-to-quarter volatility and makes near‑term guidance highly sensitive to FDA timing and partner milestones; the real test for investors is whether sustained commercial momentum (and pricing/payer wins) can replace irregular collaboration windfalls to stabilize revenue going forward.
IONS Revenue by Segment
| Period | Commercial | Research and Development | Total |
|---|---|---|---|
| Q2 2026Jun 30, 2026 | $118.60M | $149.30M | $267.90M |
| Q1 2026Mar 31, 2026 | $108.00M | $138.00M | $246.00M |
| Q4 2025Dec 31, 2025 | $141.00M | $62.00M | $203.00M |
| Q3 2025Sep 30, 2025 | $116.00M | $41.00M | $157.00M |
| Q2 2025Jun 30, 2025 | $102.76M | $349.29M | $452.05M |
| Q1 2025Mar 31, 2025 | $76.17M | $55.44M | $131.61M |
| Q4 2024Dec 31, 2024 | $86.00M | $141.00M | $227.00M |
| Q3 2024Sep 30, 2024 | $75.73M | $58.08M | $133.81M |
| Q2 2024Jun 30, 2024 | $72.04M | $153.21M | $225.25M |
| Q1 2024Mar 31, 2024 | $59.59M | $59.90M | $119.50M |
| Q4 2023Dec 31, 2023 | $79.00M | $246.00M | $325.00M |
| Q3 2023Sep 30, 2023 | $84.08M | $60.13M | $144.21M |
| Q2 2023Jun 30, 2023 | $77.90M | $110.51M | $188.41M |
| Q1 2023Mar 31, 2023 | $67.77M | $62.76M | $130.52M |
| Q4 2022Dec 31, 2022 | $80.00M | $72.00M | $152.00M |
| Q3 2022Sep 30, 2022 | $72.41M | $87.36M | $159.77M |
| Q2 2022Jun 30, 2022 | $78.18M | $55.61M | $133.79M |
| Q1 2022Mar 31, 2022 | $72.28M | $69.63M | $141.92M |
| Q4 2021Dec 31, 2021 | $87.00M | $353.00M | $440.00M |
| Q3 2021Sep 30, 2021 | $84.82M | $48.27M | $133.09M |
| Q2 2021Jun 30, 2021 | $85.86M | $39.89M | $125.75M |
| Q1 2021Mar 31, 2021 | $84.45M | $27.16M | $111.61M |
| Q4 2020Dec 31, 2020 | $96.00M | $194.00M | $290.00M |
| Q3 2020Sep 30, 2020 | $95.00M | $65.00M | $160.00M |
| Q2 2020Jun 30, 2020 | $90.00M | $56.00M | $146.00M |
| Q1 2020Mar 31, 2020 | $84.00M | $49.00M | $133.00M |

